CN104130302A - 一种核苷药物的晶型及其制备方法 - Google Patents
一种核苷药物的晶型及其制备方法 Download PDFInfo
- Publication number
- CN104130302A CN104130302A CN201410391177.9A CN201410391177A CN104130302A CN 104130302 A CN104130302 A CN 104130302A CN 201410391177 A CN201410391177 A CN 201410391177A CN 104130302 A CN104130302 A CN 104130302A
- Authority
- CN
- China
- Prior art keywords
- crystal form
- peak
- suo feibuwei
- ray powder
- powder diffraction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000013078 crystal Substances 0.000 title claims abstract description 95
- 238000002360 preparation method Methods 0.000 title abstract description 15
- 239000003814 drug Substances 0.000 title description 16
- 229940079593 drug Drugs 0.000 title description 4
- 239000002773 nucleotide Substances 0.000 title description 3
- 125000003729 nucleotide group Chemical group 0.000 title description 3
- 239000002904 solvent Substances 0.000 claims abstract description 52
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 24
- 238000000034 method Methods 0.000 claims abstract description 15
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 claims abstract description 11
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 37
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 20
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 15
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 claims description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 6
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 claims description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical group OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 5
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 claims description 4
- 150000001875 compounds Chemical class 0.000 claims description 3
- 239000012046 mixed solvent Substances 0.000 claims description 3
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 claims description 2
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 claims description 2
- 229940011051 isopropyl acetate Drugs 0.000 claims description 2
- GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 claims description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical group CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 2
- 238000000113 differential scanning calorimetry Methods 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 8
- 229960002063 sofosbuvir Drugs 0.000 abstract description 3
- TTZHDVOVKQGIBA-IQWMDFIBSA-N sofosbuvir Chemical compound N1([C@@H]2O[C@@H]([C@H]([C@]2(F)C)O)CO[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC=2C=CC=CC=2)C=CC(=O)NC1=O TTZHDVOVKQGIBA-IQWMDFIBSA-N 0.000 abstract description 3
- 239000012296 anti-solvent Substances 0.000 abstract 1
- 239000002994 raw material Substances 0.000 abstract 1
- 239000007787 solid Substances 0.000 description 29
- 230000015572 biosynthetic process Effects 0.000 description 22
- 238000005755 formation reaction Methods 0.000 description 22
- 239000000243 solution Substances 0.000 description 12
- 238000001757 thermogravimetry curve Methods 0.000 description 8
- 210000004185 liver Anatomy 0.000 description 7
- 238000001291 vacuum drying Methods 0.000 description 7
- 239000003921 oil Substances 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 241000711549 Hepacivirus C Species 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000005070 sampling Methods 0.000 description 3
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 238000002441 X-ray diffraction Methods 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 230000000737 periodic effect Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 238000010926 purge Methods 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 238000013112 stability test Methods 0.000 description 2
- 238000002411 thermogravimetry Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 229910017488 Cu K Inorganic materials 0.000 description 1
- 229910017541 Cu-K Inorganic materials 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 101800001554 RNA-directed RNA polymerase Proteins 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 238000004164 analytical calibration Methods 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052729 chemical element Inorganic materials 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 238000002788 crimping Methods 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 229910052738 indium Inorganic materials 0.000 description 1
- APFVFJFRJDLVQX-UHFFFAOYSA-N indium atom Chemical compound [In] APFVFJFRJDLVQX-UHFFFAOYSA-N 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 239000007962 solid dispersion Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- 239000012905 visible particle Substances 0.000 description 1
- 230000004304 visual acuity Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Abstract
Description
温度 | 晶型 | 溶解度 |
25℃ | 晶型6 | 1.58mg/mL |
25℃ | 晶型A | 2.15mg/mL |
37℃ | 晶型6 | 2.37mg/mL |
37℃ | 晶型A | 3.03mg/mL |
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410391177.9A CN104130302B (zh) | 2014-08-08 | 2014-08-08 | 一种核苷药物的晶型及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410391177.9A CN104130302B (zh) | 2014-08-08 | 2014-08-08 | 一种核苷药物的晶型及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104130302A true CN104130302A (zh) | 2014-11-05 |
CN104130302B CN104130302B (zh) | 2017-02-15 |
Family
ID=51803193
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410391177.9A Active CN104130302B (zh) | 2014-08-08 | 2014-08-08 | 一种核苷药物的晶型及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104130302B (zh) |
Cited By (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104447924A (zh) * | 2014-11-07 | 2015-03-25 | 南京旗昌医药科技有限公司 | 索氟布韦的晶型及其制备方法 |
CN104804054A (zh) * | 2015-04-17 | 2015-07-29 | 南京旗昌医药科技有限公司 | 一种索氟布韦的晶型及其应用 |
CN104974205A (zh) * | 2014-09-19 | 2015-10-14 | 苏州晶云药物科技有限公司 | 索非布韦的晶型a及其制备方法 |
CN105017359A (zh) * | 2015-07-08 | 2015-11-04 | 苏州晶云药物科技有限公司 | 一种索非布韦晶型的制备方法 |
WO2016023906A1 (en) * | 2014-08-13 | 2016-02-18 | Sandoz Ag | A crystalline form of sofosbuvir |
WO2016097173A1 (en) * | 2014-12-17 | 2016-06-23 | Sandoz Ag | A process for preparing a crystalline form of sofosbuvir |
CN105732751A (zh) * | 2014-12-09 | 2016-07-06 | 北京万生药业有限责任公司 | 索非布韦新晶体 |
CN105801645A (zh) * | 2014-12-29 | 2016-07-27 | 浙江海正药业股份有限公司 | 制备索非布韦晶型6的方法 |
CN105985394A (zh) * | 2015-02-26 | 2016-10-05 | 石药集团中奇制药技术(石家庄)有限公司 | 一种索非布韦新晶型及其制备方法 |
WO2016156512A1 (en) | 2015-04-01 | 2016-10-06 | Sandoz Ag | A process for preparing a crystalline form of sofosbuvir |
CN106146589A (zh) * | 2015-04-10 | 2016-11-23 | 正大天晴药业集团股份有限公司 | 氘代核苷衍生物的结晶 |
WO2017029408A1 (en) | 2015-08-20 | 2017-02-23 | Ratiopharm Gmbh | Solid state forms of sofosbuvir |
CN107427495A (zh) * | 2015-02-13 | 2017-12-01 | 桑多斯股份公司 | 包含雷迪帕韦和索非布韦的药物组合物 |
CN108084237A (zh) * | 2016-11-23 | 2018-05-29 | 广东东阳光药业有限公司 | 索非布韦的一水合物及其制备方法 |
CN108659077A (zh) * | 2017-03-27 | 2018-10-16 | 四川科伦博泰生物医药股份有限公司 | 核苷磷酰胺类化合物的晶型及制法、用途、衍生组合物 |
WO2019025600A1 (en) | 2017-08-03 | 2019-02-07 | Sandoz Ag | SOFOSBUVIR HYDRATE |
CN109467577A (zh) * | 2018-12-06 | 2019-03-15 | 南通常佑药业科技有限公司 | 一种索非布韦晶型及无定型产品的制备方法 |
EP3524234A1 (en) | 2014-06-13 | 2019-08-14 | Ratiopharm GmbH | Solid state forms of sofosbuvir |
CN109517018B (zh) * | 2018-12-29 | 2021-05-04 | 石药集团中奇制药技术(石家庄)有限公司 | 一种索磷布韦新晶型及其制备方法 |
WO2021203409A1 (zh) * | 2020-04-10 | 2021-10-14 | 南京正大天晴制药有限公司 | 一种用于治疗丙肝的无引湿性低变异性新晶型 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012012465A1 (en) * | 2010-07-19 | 2012-01-26 | Clarke, Michael, O'neil Hanrahan | Methods for the preparation of diasteromerically pure phosphoramidate prodrugs |
US20120071434A1 (en) * | 2010-09-22 | 2012-03-22 | Alios Biopharma, Inc. | Substituted nucleotide analogs |
CN102459299A (zh) * | 2009-05-20 | 2012-05-16 | 法莫赛特股份有限公司 | N-[(2′r)-2′-脱氧-2′-氟-2′-甲基-p-苯基-5′-尿苷酰基]-l-丙氨酸1-甲基乙基酯及其制备方法 |
CN102858790A (zh) * | 2010-03-31 | 2013-01-02 | 吉利德制药有限责任公司 | 核苷氨基磷酸酯 |
WO2013040492A2 (en) * | 2011-09-16 | 2013-03-21 | Gilead Sciences, Inc. | Methods for treating hcv |
CN103804446A (zh) * | 2014-02-27 | 2014-05-21 | 苏州东南药业股份有限公司 | 一种3,5-二苯甲酰基-2-去氧-2-氟-2甲基-D-核糖-γ-内酯的制备方法 |
CN103848877A (zh) * | 2013-12-16 | 2014-06-11 | 安徽贝克联合制药有限公司 | 核苷环磷酸酯化合物及其制备方法和其应用 |
-
2014
- 2014-08-08 CN CN201410391177.9A patent/CN104130302B/zh active Active
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102459299A (zh) * | 2009-05-20 | 2012-05-16 | 法莫赛特股份有限公司 | N-[(2′r)-2′-脱氧-2′-氟-2′-甲基-p-苯基-5′-尿苷酰基]-l-丙氨酸1-甲基乙基酯及其制备方法 |
CN102858790A (zh) * | 2010-03-31 | 2013-01-02 | 吉利德制药有限责任公司 | 核苷氨基磷酸酯 |
WO2012012465A1 (en) * | 2010-07-19 | 2012-01-26 | Clarke, Michael, O'neil Hanrahan | Methods for the preparation of diasteromerically pure phosphoramidate prodrugs |
US20120071434A1 (en) * | 2010-09-22 | 2012-03-22 | Alios Biopharma, Inc. | Substituted nucleotide analogs |
WO2013040492A2 (en) * | 2011-09-16 | 2013-03-21 | Gilead Sciences, Inc. | Methods for treating hcv |
CN103848877A (zh) * | 2013-12-16 | 2014-06-11 | 安徽贝克联合制药有限公司 | 核苷环磷酸酯化合物及其制备方法和其应用 |
CN103804446A (zh) * | 2014-02-27 | 2014-05-21 | 苏州东南药业股份有限公司 | 一种3,5-二苯甲酰基-2-去氧-2-氟-2甲基-D-核糖-γ-内酯的制备方法 |
Non-Patent Citations (1)
Title |
---|
刘正和: "全球首个抗HCV全口服新药索非布韦", 《山东化工》 * |
Cited By (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3845221A1 (en) | 2014-06-13 | 2021-07-07 | Ratiopharm GmbH | Solid state forms of sofosbuvir |
EP3524234A1 (en) | 2014-06-13 | 2019-08-14 | Ratiopharm GmbH | Solid state forms of sofosbuvir |
WO2016023906A1 (en) * | 2014-08-13 | 2016-02-18 | Sandoz Ag | A crystalline form of sofosbuvir |
CN104974205A (zh) * | 2014-09-19 | 2015-10-14 | 苏州晶云药物科技有限公司 | 索非布韦的晶型a及其制备方法 |
CN106083964B (zh) * | 2014-11-07 | 2018-12-18 | 南京旗昌医药科技有限公司 | 索氟布韦的晶型h2及其制备方法 |
WO2016070569A1 (zh) * | 2014-11-07 | 2016-05-12 | 南京旗昌医药科技有限公司 | 索氟布韦的晶型及其制备方法 |
CN106188195B (zh) * | 2014-11-07 | 2019-03-08 | 南京旗昌医药科技有限公司 | 索氟布韦的晶型h4及其制备方法 |
CN106046088A (zh) * | 2014-11-07 | 2016-10-26 | 南京旗昌医药科技有限公司 | 索氟布韦的晶型h3及其制备方法 |
CN106083964A (zh) * | 2014-11-07 | 2016-11-09 | 南京旗昌医药科技有限公司 | 索氟布韦的晶型h2及其制备方法 |
CN104447924A (zh) * | 2014-11-07 | 2015-03-25 | 南京旗昌医药科技有限公司 | 索氟布韦的晶型及其制备方法 |
CN106188195A (zh) * | 2014-11-07 | 2016-12-07 | 南京旗昌医药科技有限公司 | 索氟布韦的晶型h4及其制备方法 |
CN106046088B (zh) * | 2014-11-07 | 2018-05-15 | 南京旗昌医药科技有限公司 | 索氟布韦的晶型h3及其制备方法 |
CN105732751A (zh) * | 2014-12-09 | 2016-07-06 | 北京万生药业有限责任公司 | 索非布韦新晶体 |
WO2016097173A1 (en) * | 2014-12-17 | 2016-06-23 | Sandoz Ag | A process for preparing a crystalline form of sofosbuvir |
CN105801645A (zh) * | 2014-12-29 | 2016-07-27 | 浙江海正药业股份有限公司 | 制备索非布韦晶型6的方法 |
CN105801645B (zh) * | 2014-12-29 | 2019-01-04 | 浙江海正药业股份有限公司 | 制备索非布韦晶型6的方法 |
CN107427495A (zh) * | 2015-02-13 | 2017-12-01 | 桑多斯股份公司 | 包含雷迪帕韦和索非布韦的药物组合物 |
CN105985394A (zh) * | 2015-02-26 | 2016-10-05 | 石药集团中奇制药技术(石家庄)有限公司 | 一种索非布韦新晶型及其制备方法 |
WO2016156512A1 (en) | 2015-04-01 | 2016-10-06 | Sandoz Ag | A process for preparing a crystalline form of sofosbuvir |
CN106146589A (zh) * | 2015-04-10 | 2016-11-23 | 正大天晴药业集团股份有限公司 | 氘代核苷衍生物的结晶 |
CN106146589B (zh) * | 2015-04-10 | 2019-03-05 | 正大天晴药业集团股份有限公司 | 氘代核苷衍生物的结晶 |
CN104804054B (zh) * | 2015-04-17 | 2017-10-24 | 南京旗昌医药科技有限公司 | 一种索氟布韦的晶型及其应用 |
CN104804054A (zh) * | 2015-04-17 | 2015-07-29 | 南京旗昌医药科技有限公司 | 一种索氟布韦的晶型及其应用 |
CN105017359A (zh) * | 2015-07-08 | 2015-11-04 | 苏州晶云药物科技有限公司 | 一种索非布韦晶型的制备方法 |
WO2017029408A1 (en) | 2015-08-20 | 2017-02-23 | Ratiopharm Gmbh | Solid state forms of sofosbuvir |
CN108084237A (zh) * | 2016-11-23 | 2018-05-29 | 广东东阳光药业有限公司 | 索非布韦的一水合物及其制备方法 |
CN108659077A (zh) * | 2017-03-27 | 2018-10-16 | 四川科伦博泰生物医药股份有限公司 | 核苷磷酰胺类化合物的晶型及制法、用途、衍生组合物 |
WO2019025600A1 (en) | 2017-08-03 | 2019-02-07 | Sandoz Ag | SOFOSBUVIR HYDRATE |
CN109467577A (zh) * | 2018-12-06 | 2019-03-15 | 南通常佑药业科技有限公司 | 一种索非布韦晶型及无定型产品的制备方法 |
CN109517018B (zh) * | 2018-12-29 | 2021-05-04 | 石药集团中奇制药技术(石家庄)有限公司 | 一种索磷布韦新晶型及其制备方法 |
WO2021203409A1 (zh) * | 2020-04-10 | 2021-10-14 | 南京正大天晴制药有限公司 | 一种用于治疗丙肝的无引湿性低变异性新晶型 |
Also Published As
Publication number | Publication date |
---|---|
CN104130302B (zh) | 2017-02-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104130302A (zh) | 一种核苷药物的晶型及其制备方法 | |
EP3122753A2 (en) | Ibrutinib solid forms and production process therefor | |
CN104892486B (zh) | 阿普斯特的晶型b+及其制备方法 | |
CN102336801B (zh) | 醋酸阿比特龙多晶型物和药用组合物 | |
CN105085529A (zh) | 依鲁替尼新晶型及其制备方法 | |
WO2022122014A1 (zh) | Lanifibranor的晶型及其制备方法和用途 | |
CN105985394A (zh) | 一种索非布韦新晶型及其制备方法 | |
Shi et al. | A new polymorph of fenofibrate prepared by polymer-mediated crystallization | |
CN105198947B (zh) | 一种Trifluridine化合物及其药物组合物 | |
CN101768105A (zh) | 丁酸氯维地平的晶型 | |
WO2023016319A1 (zh) | Lanifibranor的晶型及其制备方法和用途 | |
CN103739639B (zh) | 一种甜菊糖a苷晶体及其制备方法和用途 | |
CN103709156B (zh) | 一种达沙替尼多晶型药物及其制备方法 | |
CN109824595A (zh) | 一种草乌甲素e晶型及其制备方法与应用 | |
CN106543105B (zh) | 一种盐酸卡利拉嗪晶型ⅳ及其制备方法 | |
CN105384724A (zh) | 一种氟代物的晶型及其制备方法 | |
CN104379557A (zh) | 阿戈美拉汀晶型i的制备方法 | |
Yang et al. | Thermodynamic stability analysis of m-nisoldipine polymorphs | |
CN108299399A (zh) | 一种小分子免疫化合物的晶型、其制备方法和含有其的药物组合物 | |
CN106995434A (zh) | 一种三唑类抗真菌药的晶型及其制备方法 | |
CN106632373A (zh) | 一种岩白菜素的d晶型固体物质及其制备方法与用途 | |
CN107245054A (zh) | 一种无定形草乌甲素化合物及其制备方法 | |
CN103130795A (zh) | 卢拉西酮盐酸盐的晶体a及其用途 | |
CN108727417B (zh) | 多环化合物钠盐及其多晶型、制备方法及应用 | |
CN114258395A (zh) | 一种酯化合物的晶型及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: RUYUAN HEC PHARM CO., LTD. Free format text: FORMER OWNER: GUANGDONG DONGYANGGUANG PHARMACEUTICAL CO., LTD. Effective date: 20150515 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20150515 Address after: Dam zone 512721 Guangdong city of Shaoguan province Ruyuan Yao Autonomous County town of dragon bay Hou Gong Du milk Applicant after: RUYUAN HEC PHARM Co.,Ltd. Address before: 523808 Guangdong city of Dongguan province Hubei Songshan Industrial Park Industrial Road No. 1 Applicant before: SUNSHINE LAKE PHARMA Co.,Ltd. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Crystal form of a nucleoside drug and its preparation method Effective date of registration: 20201215 Granted publication date: 20170215 Pledgee: Guangdong Ruyuan Rural Commercial Bank Co.,Ltd. Pledgor: RUYUAN HEC PHARM Co.,Ltd. Registration number: Y2020990001445 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20230310 Granted publication date: 20170215 Pledgee: Guangdong Ruyuan Rural Commercial Bank Co.,Ltd. Pledgor: RUYUAN HEC PHARM Co.,Ltd. Registration number: Y2020990001445 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: The crystal form of a nucleoside drug and its preparation method Effective date of registration: 20230317 Granted publication date: 20170215 Pledgee: Guangdong Shixing Rural Commercial Bank Co.,Ltd. Pledgor: RUYUAN HEC PHARM Co.,Ltd. Registration number: Y2023980035185 |